This Nasal Spray Rapidly Reverses Effects Of Fentanyl Overdose And No, It's Not Naloxone
Indivior announced on Monday results from a pharmacodynamic study demonstrating that OPVEE rapidly reverses opioid-induced respiratory depression, the major cause of deaths due to opioid overdose. Titled "Reversal of opioid-induced respiratory depression in healthy volunteers: comparison of intranasal nalmefene and intranasal naloxone", the study was published in the Journal of Clinical Pharmacology. It was part of the OPVEE development program and reviewed by the FDA as part of the approval process. The research was focused on a head-to-head comparison examining the effects of 2.7 mg intranasal (IN) nalmefene (OPVEE) and 4 mg IN naloxone on opioid-induced respiratory depression. The findings showed that OPVEE reversed the respiratory depression produced by remifentanil – which is a synthetic opioid related to fentanyl - during the first 5 minutes following the administration.
